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Recombinant annexin II mutants were generated to identify amino acids involved in the formation of the discontinuous cpitope of the monoclonal 
antibody H28. Analysis of the various mutant proteins by immunoblotting and enzyme-linked immunosorbent assay revealed that residues Lysz7, 
Arg2, GW, and Arg7 are indispensable for H28 reactivity. Residues in equivalent positions are also in close proximity in the recently determined 
X-ray structure of annexin V, a different member of the same family of Ca’+/lipid-binding proteins. Thus annexins II and V show a similar three- 
dimensional folding in this region of the molecule. Consequently, !he Ca** binding sites and the residues phosphorylated by pp601~ (Tyti’) and 
protein kinase C (Setis) most likely reside on opposite sides of the annexin II molecule. 
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1. INTRODUCTION 
Increasing interest has focused on a still growing 
family of Ca’+- and phospholipid-binding proteins. 
Originally referred to as lipocortins, calpactins and en- 
donexins, they are now generally termed annexins [I]. 
All members of this family consist of segments of 70-80 
amino acids, which are repeated either 4 times (32-39 
kDa annexins) or 8 times (68 kDa annexin) and com- 
prise the so-called core (for review see [a-6]). The in- 
dividual segments (also known as annexin repeats) 
share a high degree of sequence homology which is par- 
ticularly pronounced over a stretch of 17 amino acids 
known as the ‘endonexin’ fold [7]. The annexin core is 
defined by its resistance to limited proteolysis. It 
displays a remarkably high a-helix content [8] and har- 
bors the binding sites for Ca”’ and phospholipid [9-l l] 
which partly reside within the endonexin fold [ 12,133. 
In each annexin, the core is preceded by a protease- 
sensitive N-terminal tail which is variable in sequence 
and length. 
Annexin II, one member of the family, was recogniz- 
ed as a major cellular substrate for the tyrosine protein 
kinase encoded by the SI’C oncogene 114-161. 
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Phosphorylation occurs at TyrZ3 in the N-terminal tail 
[17], which also harbors a protein kinase C site (Serts) 
[18,19]. The tail of annexin II also contains the binding 
site for the cellular protein ligand pll [9,10,19-211. 
Both pll binding, which leads to the formation of a 
~362~112 heterotetramer, and phosphorylation by 
pp60src alter properties displayed by annexin II, e.g. an- 
nexin II phosphorylated at Tyr23 has an increased 
Ca2 + -requirement for phospho!ipid binding when com- 
pared with the non-phosphorylated form [22]. Thus the 
N-terminal tail seems to regulate physiological func- 
tions of annexin II, which are thought to include mem- 
brane fusion events during exocytosis and/or the mem- 
brane-cytoskeletal linkage (for review see [23,24]). 
A structural basis for the regulatory role of the N- 
terminal tail on properties displayed by the core stems 
from the preliminary mapping of a discontinuous 
epitope. Johnsson et al. [25] showed that residues 25-28 
of the tail, as well as residue 65, which is close to the 
first endonexin fold of the core, are involved in the for- 
mation of the epitope for the monoclonal antibody 
H28. Here we have generated site-specifically mutated 
annexin II molecules which allow the precise descrip- 
tion of the H28 epitope. Our results show that in the 
region of the H28 epitope, the three-dimensional 
folding of annexin II must be highly similar to that of 
annexin V, which was recently determined by X-ray dif- 
fraction [8,12]. Thus the phosphorylation sites (TyrZS, 
Serts) and the Ca2+ -binding sites most likely reside on 
different sides of the molecule, and an enhanced 
Ca2 + -requirement in phospholipid binding of the 
pp60src phosphorylated annexin II [22] must be explain- 
ed by phosphorylation-induced conformational 
changes. 
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2. MATERIALS AND METHODS 
Cloning and purification of human recombinant annexin II have 
been described [13]. Briefly. the complete human cDNA was ligated 
into the expression vector pDS 10 [26] and transferred into E. co/i JM 
101 using standard procedures. The insoluble recombinant protein 
was recovered as inclusion bodies [27], dissolved in buffer containing 
9 M urea and treated batchwise with Q-Sepharose (Pharmacia LKB) 
and CM-52 (Whatman). Following renaturation by dialysis against 
renaturation buffer (20 mM imidazole-I-ICI, pH 7.5, 100 mM NaCI, 
2 mM NaNr. 1 mM EGTA, 1 mM DTT) further purification was car- 
ried out as described for the isolation of annexin II from porcine in- 
testine [16]. In vitro mutagenesis was performed following the 
method of Eckstein and co-workers [28] using an Amersham kit. 
Positive clones were characterized by dideoxy sequencing using a 
T7-sequencing kit (Pharmacia). 
The o-chymotryptic core of human recombinant annexin II was ob- 
tained with an enzyme to protein ratio of 1:7S at room temperature 
for 20 min [IO]. Digestion was stopped with 2 mM phenylmethyl- 
sulfonylfluoride. 
Due to the cloning strategy, all recombinant proteins start with the 
sequence MRGSFK prior to the annexin II coding sequence. These ad- 
ditional 6 residues are introduced by the pDS 10 expression vector. 
The N-terminal sequences of the recombinant annexin II and the 
chymotryptic core were confirmed by direct protein sequencing on an 
Applied Biosystems gas-phase sequenator (model 470A). Im- 
munoblotting (291 and enzyme-linked immunosorbent assays [30] 
were carried out using standard procedures. The murine monoclonal 
antibody H28 has been described (311. Peroxidase labelled swine anti- 
mouse IgGs (Dako) were used as second antibodies. 
3. RESULTS 
The previous proposal that the murine monoclonal 
antibody I-I28 recognized a discontinuous epitope in- 
volving at least Glu6’ and one or more residue(s) bet- 
ween Serzs and Lys*’ of porcine annexin II was essen- 
tially based on two sets of observations. Proteolytic 
derivatives lacking less than 25 residues at the N- 
terminus retained reactivity in Western blots, while the 
loss of an additional 2 residues yielded non-reactive an- 
nexin II cores. The limited cross-species reactivity of 
H28 seemed explained by the finding that the reactive 
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Fig. 2. Western blot analysis uf different annexin 11 mutants. (A) 
Poinceau staining of the proteins separated in 12.5% SDS 
polyacrylamide gels and transferred to nitrocellulose, (B) immunos- 
taining of the nitrocellulose filters shown in A with H28 and perox- 
idase coupled anti-mouse IgGs. Lanes: 1. human wild type A65; 2 
S25D; 3, V26A; 4. K27A; 5. R62Q; 6, A65E; 7, R67M; 8 and 9 corres- 
pond to 6 and 7 on a second blot; 10, A65E chymotryptic core. 
annexins II of pig, cow and chicken display a glutamic 
acid in position 65, while in the non-reactive annexins II 
of man and mouse, residues 65 is an alanine (in the 
former case) or a valine (in the latter) [25]. To assess 
these predictions and to identify the I-I% epitope in 
more detail, we have generated recombinant human an- 
nexin II and several mutant derivatives (Fig. 1). Recom- 
binant proteins were expressed in E. coii, purified to 
homogeneity and analyzed by immunoblotting and 
ELISA. 
Fig. 2 shows that the recombinant human annexin II 
is not recognized by I-I28 in immunoblotting. When a 
single amino acid replacement, substituting glutamic 
acid for Ala65, is introduced, the resulting protein 
(A65E) is fully reactive. This reaction is lost when the 
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Fig. 1. .Amino acid substitutions in different annexin II mutants. The N-terminal 82 residues of wild-type human annexin II are given in the upper 
row (A65). Substitutions present in the different mutants arc indicated below. 
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Fig. 3. ELISA of the different annexin 11 mutants and the H28 
rnonoclonal antibody. Purified proteins were bound overnight at 4°C 
to Dynatech microtiter plates with concentrations ranging from 5 to 
640 @ml. Saturation and antibody incubations were performed for 
2 h in 10% horse serum. 2 mM PMSF was added at all steps. The dye 
reaction using 1.2-phenylenediamine was analyzed measuring the op- 
tical density (OD) with a Dynatech photometer. 
N-terminal 28 residues are removed by chymotrypsin 
(compare slots 1,6,8 and 10). Based on this result, all 
further annexin mutants were derived from the A65E 
clone, i.e. position 65 was kept as glutamic acid. Fig. 2 
shows that R62Q has no PI28 reactivity, while R67M 
and K27A react only very weakly with the antibody. In 
contrast, S25D and V26A display a reactivity com- 
parable to that of the A65E parent molecule. 
All recombinant annexins were also directly assayed 
as native proteins in an ELBA (Fig. 3). The nearly iden- 
tical titration curves of A65E and V26A were only 
moderately lowered in S25D. The two mutants W67M 
and R62Q showed a low reactivity, which became detec- 
table only at high concentrations. Wild-type human an- 
nexin II (A65) and the core of A65E reacted only at 
background levels. The sole difference between im- 
munoblotting and ELBA concerns mutant K27A, 
which showed moderate reactivity in the ELISA and 
hardly any reaction in blotting. 
4. DISCUSSION 
Use of recombinant annexin II molecules and single 
point mutations introduced by site-directed mutagene- 
sis confirms and greatly extends the previous character- 
ization of the discontinuous H28 epitope [25]. Most im- 
portantly, substitution of alanine 65 in the non-reactive 
human annexin by glutamic acid, the residue present in 
the reactive species from pig, cow and chicken, provides 
a fully reactive molecule. In addition to glutamic acid 
65 we have now identified arginines 62 and 67 as further 
contact points. The second part of the epitope involving 
the segment around residues 25 to 27 is indicated by the 
finding that a proteolytic derivative starting at position 
25 is fully active, while derivatives shortened by two 01 
four additional residues have lost reactivity (see also 
Figs. 2 and 3). Point mutations in this region have either 
no effect (V26A), a very small reduction in affinity 
(StSD) or only a moderate effect (K27A). Thus in this 
region the antibody may detect the conformation of the 
protein and/or the protein backbone rather than a 
specific side chain. 
The discontinuous H28 epitope is easily understood 
with the recently established X-ray structure of annexin 
V [8] which is a different member of the protein family 
showing 42010 sequence identity to annexin II. This se- 
quence homology, as well as the H28 epitope mapping, 
allow the prediction that annexin II has a very similar 
three-dimensional folding. In the annexin V structure, 
each of the four annexin repeats is built by 5 tightly 
packed helices (a to e) connected by short turns. The 
lower concave surface of the folded annexin V molecule 
carries the N-terminal tail [g], while presumptive Cat + 
binding sites locate to the upper convex surface [It]. 
Lys*‘, Arg62, Glu6’ and ArgG7, the currently identified 
positions of the H28 epitope, correspond in the linear 
sequence alignment to residues 10,45,48 and 50 of an- 
nexin V 1321. In the crystal structure of annexin V, the 
cr-carboq distances petween positions 10 and 45 or 48 
are 6.8 A and 9.8 A respectively (R. Huber, personal 
communication). Since this is well within the range of 
an antibody binding site (for review see [33]j, the 
equivalent residues in annexin II (positions 27 and 62 or 
65) are likely to be folded in a similar way. Thus Lys2’ 
is situated 6 residues prior to helix la, Arg”2 close to the 
C-terminal end of helix lb and GIu~~ and Arg6’ in the 
N-terminal part of helix lc. All residues involved in the 
formation of the epitope are located on the concave side 
of the molecule. 
The similar structure of annexin II and V raises an in- 
teresting problem as to the enhanced Ca2+-requirement 
in phospholipid binding of annexin II phosphorylated 
at Tyr”. While this residue lies on the concave side, 
Ca’+ binding sites are thought to occur exclusively on 
the convex side [la]. Thus it seems that a conforma- 
tional change induced by phosphorylation is responsi- 
ble for the altered Ca’+/lipid-binding properties. 
Whether this conformational change involves the pore, 
which transverses the annexin molecule and is thought 
to be a voltage dependent Ca* ’ channel [8,12], is not 
known. It seems however important that all regulatory 
elements of annexin II, the phosphorylation sites for 
kinase C and pp60”” at Ser23 and Tyr2’, as well as the 
pl 1 binding site at residues 1 to 14 are probably situated 
in close proximity to the entrance of the pore. 
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